PAS - Prostate Analysis System, an AI-based product that beats expert human Pathologists Passed
Tuesday May 17, 2022 13:00 - 13:30 A5
Lecturer: Ewert Bengtsson
1.4 million people are diagnosed with prostate cancer each year worldwide. Prostate cancer the most common cancer form among men and is generally a slow growing cancer. Treatment might lead to impotence and incontinence, but if the cancer is allowed to spread outside the prostate it is often fatal.
The challenge the healthcare is facing is to properly diagnose the cancer to be able treat it correctly, at the right moment, to maximize survivability and quality of life. The decision for treatment is based on the aggressiveness of the cancer, in which the current standard methods have problems with correlation to outcome and reproducibility.
PAS is trained on a world-unique database of almost 20,000 patients with outcome follow-up for up to 20 years, to create a risk assessment score directly connected to the actual outcome of the patients.
Learn why outcome-based AI systems can outperform human pathologists and why reproducibility is so important to the diagnosis chain, and what PAS will bring to the benefit of prostate cancer patients.
Language
English
Topic
AI
Seminar type
Live
Objective of lecture
Verktyg för implementering
Level of knowledge
Fördjupning
Target audience
Chef/Beslutsfattare
Politiker
Verksamhetsutveckling
Upphandlare/inköp/ekonomi/HR
Omsorgspersonal
Vårdpersonal
Patientorganisationer/Brukarorganisationer
Keyword
Nytta/effekt
Välfärdsutveckling
Innovativ/forskning
Appar
Användbarhet
Lecturers
Ewert Bengtsson Lecturer
Professor emeritus
Spearpoint Analytics AB
Ewert Bengtsson is an image analysis researcher focusing on microscopy and cancer diagnostic applications. After retiring from his position as professor at Uppsala University he together with another researcher and business people took the initiative of creating the company Spearpoint Analytics. The mission of the company is to bring research results showing superior ability to predict the outcome of prostate cancer based on AI supported image analysis of tissue sections to use as a medical product.